Rapid health evaluation in migrant peoples in transit through Darien, Panama: Protocol for a multi-method qualitative and quantitative study

Authors and affiliations:

Amanda Gabster, PhD*	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá *corresponding author
Monica Jhangimal, MD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Jennifer Toller Erausquin, PhD	University of North Carolina at Greensboro, USA
José Antonio Suárez, MD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá., National Research System, Secretariant of Science, Technology and Innovation, Panama
Justo Pinzón-Espinosa, MD, MSc	Hospital Universitario Parc Taulí, Sabadell, España
Madeline Baird, MSc	University of Connecticut, USA
Jennifer Katz, BSc	Community Development Network of the Americas, Panamá
Davis Beltran-Henríquez, PhD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Gonzalo Cabezas-Talavero, MSc	Community Development Network of the Americas, Panamá
Andrés F. Henao-Martínez, MD	University of Colorado Anschutz Medical Campus, USA
Carlos Franco-Paredes, MD	University of Colorado Anschutz Medical Campus, USA and Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico
Nelson I. Agudelo-Higuita., MD	University of Oklahoma Health Sciences Center, USA
Mónica Pachar, MD	Hospital Santo Tomás, Panamá
José Anel González, MD	Hospital Irma De Lourdes Tzanetatos, Panamá
Fátima Rodriguez, MSc	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Juan Miguel Pascale, MD, PhD	Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá
Migrant Peoples in Transit Study Group	Joanne Sánchez, Nathan Gundacker, Candy Nakad, Yamitzel Zaldívar, Fátima Rodriguez, Grace Vistica, Daniel Owen, Thomas Rincón, Máximo Gonzalez, Miliza Peralta, Florence JN Pierre, Stevenson Pierre, Miliza Peralta, Nelsón Cabezón, Eugenia Millender, Daniel Viquez, Anyi Yu Pon

Keywords: migrant peoples, Latin America, health equity, tropical medicine, Darien

WC: 3684

Abstract

Background:

The world is currently unprepared to deal with a the drastic increase in global migration. There is an urgent need to develop programs to protect the well being and health of migrant peoples. Increased population movement is already evident throughout the Americas as exemplified by the rising number of migrant peoples that pass through the Darien neotropical moist broadleaf forest along the border region between Panama and Colombia. The transit of migrant peoples through this area has an increase in the last years. In 2021 an average of 9,400 people entered the region per month compared to 2,000-3,500 people monthly in 2019. Along this trail, there is no access to healthcare, food provision, potable water, or housing. To date, much of what is known about health needs and barriers to healthcare within this population is based on journalistic reports and anecdotes. There is a need for a comprehensive approach to assess the healthcare needs migrant peoples in transit. This study aims to describe demographic characteristics, mental and physical health status and needs, and experiences of host communities, and to identify opportunities to improve healthcare provision to migrant peoples in transit in Panama.

Study design and methods:

This multi-method study will include qualitative (n=70) and quantitative (n=520) components. The qualitative component includes interviews with migrant peoples in transit, national and international non-governmental organizations and agencies based in Panama. The quantitative component is a rapid epidemiological study which includes a questionnaire and four clinical screenings: mental health, sexual and reproductive health, general and tropical medicine, and nutrition.

Conclusion:

This study will contribute to a better understanding of the health status and needs of migrant peoples in transit through the region. Findings will be used to allocate resources and provide targeted healthcare interventions for migrant peoples in transit through Darien, Panama.

Introduction

Currently, there are 281 million international migrant peoples worldwide, which is three times greater than the number of migrant peoples estimated in 1970 (1). Additionally, the number of forcibly displaced people worldwide has risen dramatically in the past decade (2). The world is currently unprepared to deal with population movement of this scale, and there is an urgent need to develop programs to protect the well being and health of migrant peoples. A dramatic increase in population movement is evident through the Americas, where migrant peoples from Africa, Asia, South America, and the Caribbean travel through South and Central America en route to North America. Although other portions of the route may involve travel by air, train, or bus, migrants who arrive in South America headed north must travel on foot through the Darien National Forest along the border region between Panama and Colombia.

The Darien Forest (DF), commonly called the 'Darien Gap,' is a roadless, dense, 106 km long neotropical moist broadleaf forest that interrupts the Panamerican Highway and serves as a natural barrier between Colombia and Panama. The crossing — through what is known to be "the most dangerous and inhospitable" jungle in the world— is a treacherous journey, often taking between seven to fourteen days depending on the route taken, the amount of food carried, and travel group members' abilities (3). Migrant peoples who travel this route have no access to potable water or food and must face deadly river crossings, scorching high temperatures, and poisonous animals. Some indigenous communities situated along the dense forest's outskirts provide a temporary resting place for migrant peoples in transit. Drug traffickers also share the trails, and people who have made the journey have commonly reported human trafficking, smuggling and violence. Moreover, from May to September 2021, 180 cases of rape were reported to Doctors Without Borders (4).

The National Border Police (SENAFRONT) guides migrant peoples who emerge from the Gap to 'Migrant Reception Stations' (MRS), organized by the National Migrant Services. All individuals who enter by foot into Panama, with very few exceptions, pass through these MRS. These posts are part of the international 'controlled flow' of migrant peoples in a coordinated effort between the United States of America (USA) and Panama, where biometric measurements are taken of all individuals entering the country to screen for terrorism and keep a document trail

of individuals (5, 6).   Time spent at the MRS depends on several factors including the individual's nationality, health needs and demographics. Citizens of some countries are allowed to pass quickly, while others may need to wait months for their migration process in Panama. Individuals from South America and the Caribbean (except Haiti and Cuba) are among those who have non-expedited processes and these nationals who arrive in Darien must go through lengthy months-long visa processes before continuing. Citizens from other countries often stay in the Darien MRSs for approximately 3-14 days before being transported to another MRS near the Panama-Costa Rica border, where they will remain until initiating their travels north.

From 2015 to 2021, there has been a steady increase in the number of migrant peoples in transit that pass through the DF at the Colombia-Panama border en route to North America (7-9). Prior to 2020, there were between 2,000-3,000 individuals who crossed into Panama monthly through the DF. These trails have been used for centuries to cross between the two countries, however, from 2016 onwards the number of people using this route has increased annually. From January to September 2021, more than 91,000 migrant peoples entered Panama through the DF (10). This recent increase follows a period early in the COVID-19 pandemic where a large number of people were unable to cross international borders (8, 11).   Additionally, perceptions of the United States' changes in immigration policies with the Biden administration has been identified as impacting the number of migrant peoples through these routes (12). Individuals who make this journey come from different countries (Map 1). According to official records from Panama's National Migration Service, over 70% are Haitian citizens, 20% Cuban citizens, and the remaining 10% originate from Sub-Saharan Africa, Asia, and South America (8). Furthermore, from 2018, there has been an increase in children, families, and pregnant women entering Panama on foot through the DF (8, 13). Individuals from outside the continent arrive in South America by land or sea, often arriving in Ecuador or Brazil, beginning their journey by land up to the Panama-Colombia border (7-9).

There is no access to healthcare along the route through the DF and very limited access to needed health services while in the MRSs. During the DF crossing, migrant peoples are exposed to dangerous elements from the days spent in the tropical forest and people encountered during their route. These elements are coupled with increased prevalence of diseases and health

conditions common in their countries of origin prior to beginning their route through Darien. In recent years, Panama's Ministry of Health (MINSA) and some international organizations have provided resources to begin to address the health needs and offer healthcare to migrant peoples in transit at the MRS. However, the COVID-19 pandemic has reoriented healthcare service provision, where healthcare is focused on SARS-CoV-2 diagnosis and quarantine; however other services such as general health, sexual health, mental health, reproductive medicine and fever management have been left aside (14, 15). PAHO has recommended in their priority actions a need to strengthen surveillance and monitoring of the prevalence of health conditions through: [1] the development of comprehensive profiles of the health status of migrants, and [2] strengthening of national and decentralized health surveillance systems, especially in the border-transit areas that can capture the health status and needs of migrants (16). In accordance with these recommendations, this study protocol is intended to be a rapid assessment of migrant peoples' health status, needs, impact on surrounding communities, and opportunities for improved service provision to this population. Results from the study will inform future healthcare for migrants in transit in Darien and the region.

Methods

Study design and population
This study will use both qualitative and quantitative cross-sectional methods. We will use qualitative research methods to capture the perspectives and experiences of migrant peoples in transit and stakeholders (Table 1). Additionally, we will use qualitative research to learn from the experiences of a variety of stakeholders, including those who provide services, design and allocate resources to programming, and individuals that live in the communities where migrants pass while crossing the DF. Participants within the study's qualitative component include government health and migration personnel, representatives from international organizations working with migrant populations, community members from surrounding host communities, and migrant peoples.

The qualitative component (Component A) will use purposive sampling and undertake semi-structured interviews, focus groups and select participant observation to assess health needs and service provision to migrant peoples (Table 2). Qualitative data collection tools (i.e., semi-

structured interview guides for each stakeholder group) will be designed to capture data to describe divergent health priorities and available health services, evaluate patient barriers for accessing health services, and document needed resources for improving healthcare provision according to stakeholder perspectives. Through coding and thematic analysis of interviews, results of the qualitative component will allow our research team to contextualize prevalence data from the quantitative study component. The qualitative component will provide insights from key stakeholder groups, in their own words. Interviews will provide rich descriptions of the migrant experience and health needs of migrants in transit through Darien, as well as challenges to health services provision. We will use this information to prioritize needs and identify targets and strategies for future intervention.

The quantitative component (Component B, Table 1) includes a rapid epidemiological study among migrant peoples in transit. This component will include a self-administered questionnaire, and four clinical screenings: mental health, sexual and reproductive health, general and tropical medicine, and nutrition. Age of inclusion for each subcomponent can be found in Table 2. The self-administered questionnaire (Supplementary material A) includes demographics, migration routes, sexual and reproductive health and behaviours and self-reported health. This questionnaire was developed from existing instruments (some modified for this population) (17-26). For the clinical laboratory components, participants will be asked to provide a mid-stream urine sample and a peripheral blood sample for laboratory point-of-care screenings for the following infections/conditions: hepatitis A,B,C and E, Chagas disease, malaria, dengue, chikungunya, HIV, syphilis and pregnancy (Table 3). Further rapid testing will be applied, according to clinical presentations, as indicated in Table 4. Clinical screening will include a review of the present and past medical history, vital signs, body measurements and a physical examination. On-site treatment (Table 5) and/or referral to primary, secondary or teritiary centers will be organized (supplementary material B) according to clinical and laboratory findings.

Sample size calculations:

To determine the required sample size for (1) participants aged ≥18 years, and (2) participants aged <18 years in this cross-sectional, observational study, we used $n = \frac{Z^2 P(1-P)}{d^2}$ where n is the

sample size, Z the confidence statistic, P is expected prevalence and d is the precision (27). Based on a past survey by the International Migration Organization, we expect 16% of migrant peoples in transit in Panama with gastrointestinal diseases; this prevalence was used for sample size calculation (28). The sampling frame composed of a total population expected to enter the MRS (2500; 20% of those are <18 years). In total, 120 participants <18 years and 160 participants ≥18 years will be included. We have a larger planned sample for the questionnaire, as we expect over half of these individuals will consent to filling out the questionnaire but not be willing to participate in the more time-consuming clinical components.

Ethical considerations

This study has approval from the *Comité de Bioética de la Investigación del Instituto Conmemorativo Gorgas de Estudios de la Salud* (260/CBI/ICGES/21). Participants 18 years and older will be asked to read a study information sheet and sign the informed consent form. Participants 12-17 years will have their guardian read and sign the guardian information sheet and informed consent form, and the participant will be required to read and sign the informed assent form. Participants <12 years will be required to have a guardian read and sign the informed guardian consent form. Participants will not be offered monetary compensation for their participation. However, a small snack (valued at less than $3.00) will be provided. All participants will be given educational sheets that cover the syndromes and infections tested for, and these sheets will be posted publicly at the MRSs. The consent forms, assent forms, questionnaire, and educational materials will be available in Spanish, English, French, Haitian Creole, and Portuguese languages.

Participant selection

In Component A, we will use purposive sampling. Community leaders will be asked to attend *focus group interviews*, and institutional, national, and organization leaders will share their perspectives through *individual semi-structured interviews*. A group of migrant peoples will also be selected to participate in *individual semi-structured interviews*. Select migrants accessing health services may be accompanied to observe their experiences within available healthcare providers. A total of 70 participant interviews and focus group discussions are anticipated within the qualitative study component, as this number is expected to allow us to reach saturation in capturing stakeholder perspectives and experiences.

In Component B, participants will be included systematically, where groups of 40-50 individuals arrive at the MRS where the sampling will be undertaken. When lined up to be registered with the Migration Service, small invitation cards will be given to every 1:n person from each stratum. The n will be calculated at the start of each day and depends on the number of expected strata to arrive each day, to include between 30-50 participants daily. After the person finalizes the migration registration process, they will be asked to join the study group at the respective study tents. Inclusion and exclusion criteria are dependent on the study component, as outlined in Table 2. As potential participants may be at the MRS for an undetermined amount of time, this study will only include participants who do not have a planned exit from the MRS within 8 hours.

Data capture:

Data capture will differ by study component and methods employed. Component A will include participant observation, semi-structured interviews, and focus groups captured via ethnographic fieldnotes and recorded on a digital recorder. Interviews and focus groups will be conducted in Spanish and, if needed, interviews with migrant persons will be undertaken in English and through real-time interpreters of French, Portuguese, or Haitian Creole. Component B will include a self-administered questionnaire on a tablet using *Kobo Toolbox Software* (Harvard Humanitarian Initiative, Cambridge, MA), and will be stored on the device under the participant´s code until wifi is available. Clinical and laboratory information will be inputed into *Kobo Toolbox* with a separate entry for each participant.

Pharmacological and psychological treatment and referral:

On-site treatment by study subcomponent is found in Table 5. If the participant needs to be referred to primary, secondary or teritiary facilities for further care (Supplementary Table B), this will be organized by the study team and the participant will be transported with no cost to them.

Pharmacological treatment

On-site pharmacological treatment will be given according to the severity of the affectation. A higher level of care will be arranged if needed to on-site or referral to the nearest health center in the town of Meteti or to the secondary and tertiary hospitals, in Chepo and Panama City, respectively. The field clinic where the study is undertaken is rudimentary and will not attend to all needs. Therefore some cases will be referred to health centers and hospitals where a) the condition requires further testing or specialized care, or b) treatment is intravenous or daily injections, as described in Table 5.

Psychiatric care and treatment

Following the RHS-15 screening and meeting with the psychiatrist, individuals who would like to participate in group-oriented therapy are welcome to attend language-based sessions. Additionally, at any time, if the participant seems in distress, presents with acute psychosis or self/heteroagression, immediate consultation with an on-site psychiatrist will be done. Treatment protocol is summarized in Table 5 according to syndromic presentations.

On-site management of distress:

At any time during the study, if a participant is anxious, depressed, or distressed, the "Distress Protocol" will be activated (Supplementary material C). The "Violence Protocol" will be implemented for individuals who report sexual violence during the qualitative component, questionnaire, or clinical exam (Supplementary material D). These are based on the Ministry of Health procedure for sexual violence, rape, incest, and a previously published protocol for children who report violence that has been used in previous studies in Panama and worldwide (23, 29).

Lab and clinical results

The laboratory POC tests and clinical results will be given to every participant in paper format the day they are included in the studies. All results will be explained to the participants at the time results are offered. The results will also be found in a password-protected location on the Gorgas Memorial Institute for Health Studies' webpage. Each participant will have access to a secure portal for one year, which will house their study results and educational sheets. The

portal will be accessible from a phone or computer. The participants' access information and password will be clipped into their passports.

Data analysis plan

Data analysis will depend on the study component.

For Component A, recordings and fieldnotes will be transcribed; all identifying information will be deleted. The recorded files will be destroyed after the transcription. Transcripts will be coded by MB and AG using *Nvivo* software. Both coders will work independently and codes will be compared, discussed and discrepancies will be resolved. Transcripts will be saved on an encrypted external hard drive. The data will be analyzed with a thematic analysis method and in an essentialist manner, meaning the participant experiences will be revealed. Transcripts will then be coded at a manifestation level to include the main themes. It is also possible that some codes emerge inductively from the data. This hybrid method of analysis from the data has been previously described and demonstrated to be rigorous (30). A thematic map will be constructed, revised, and altered based on team discussions; contradictions and negative cases will be identified and presented.

For Component B, descriptive and analytical methods will be used to describe the findings of the quantitative questionnaire, including sociodemographic factors, sexual and reproductive biography, sexual behaviors, non-consensual sexual relations, self-reported health, family whereabouts, and social wellbeing. In addition, the prevalence of laboratory and clinical diagnoses will be presented for the sample as a whole, as well as for key subgroups, including men, women, adults and young persons. Quantitative questionnaire responses will be used to describe the epidemiology of test positivity and diagnoses. Sociodemographic and behavioral variables that are significantly associated with health outcomes of interest in bivariable analyses will be included in multivariable regression models to estimate strength of adjusted associations and test their significance.

Discussion

By 2050, the UN estimates that over 1 billion people could be displaced due to climate change alone (31, 32). Many others are leaving their country of origin for work, family, conflict, persecution, and natural disasters (32). This increase in population movement is already evident throughout the Americas, especially in Panama, where migrants from different Caribbean regions, South America, Africa, and Asia, travel through South and Central America en route to North America. Unfortunately, the world and Latin America are not prepared to provide medical care for mass migration.

PAHO has highlighted a need to strengthen both, health surveillance and the monitoring of existing programs targeted towards migrant peoples in the region (16). This rapid evaluation of health status and service provision among migrant peoples in transit aims to respond to this evidence gap. Employing a mixed qualitative and quantative approach, the study will investigate the health status and needs among migrant peoples in transit passing through the Darien MRSs. Currently, individuals with acute illness or emergency health conditions, such as pregnancy, may be transferred to nearby MINSA health centers. However, the occurrence of other health conditions, such as anxiety, PTSD, depression, genito-urinary syndromes and tropical diseases, as well as mal/under-nutrition, remain largely undetected and ignored; information related to their prevalence among migrant peoples in transit through the region remain widely unknown.

As the demographics of migrants who opt for this perilous route shift, information related to the health needs of this population and opportunities for strengthening service provision at the MRS and regionally for migrant peoples in transit is essential. This study is critical to understand health priorities, especially with infectious and tropical disease, nutrition, mental health and sexual and reproductive health of those who pass thorough the DF. Additionally, findings could be used to optimize scarce resources targeted towards improving the wellbeing of migrant peoples who pass through this region. Previous research among people in transit in Central America and Mexico has led to recommendations to decriminalize irregular migration (33); identify and stop human trafficking, particularly of women and children (33); and expand the number of migrants' shelters as a way to meet basic needs (34). Further, studies recommend

better coordination and collaboration among governmental and non-governmental organizations—and across borders—to prevent and control health problems faced by migrant people in transit (34). Further, researchers recommend improving access to primary healthcare, including STI and HIV testing, among this population (34, 35). To ensure that the results of this project inform programs and policies for migrants in transit, results and targeted intervention recommendations that will have emerged from the qualitative and quantitative studies will be presented locally to MINSA and international non-governmental organizations that focu on service provision to migrant peoples.

Access to health care is a human right—increasing migrant health and health literacy translate into future social engagement, citizenship, and productivity (36). The overarching goal of this project is to document the health needs of migrant peoples in transit who pass through Panama in order to provide initial surveillance information and recommendations for targeted interventions for this mobile population. To do this, the project will use point of care testing and a comprehensive, easily deployable package of health services. Strengthening point of care diagnosis and service delivery will be essential to address barriers to quality health care for migrant peoples that frequently have insufficient time to receive provider follow-up and continuity of care. The literature from other contexts of migration indicates that strategies to screen and treat migrant populations for transmissible diseases, including tuberculosis, hepatitis B, hepatitis C, HIV infection, enteric bacteria, and helminths, can be both impactful and cost-effective (37) in the control of infectious disease. Addressing these unmet health needs and improving service provision can help alleviate the incredibly marked inequities migrant peoples have experienced and sustained in their journey.

The challenges to deploy and deliver a point of health care for migrant peoples in transit are enormous—facing barriers including discrimination, violence, communication and insufficient access to healthcare (4, 38). Such issues have described a perceived idea of 'deservingness' that categorizes patients, particularly migrant peoples, as more or less deserving of access to quality health care (39). There are few published data on healthcare needs of migrant peoples in transit through Latin America in route to USA. Grey literature from UN and other international NGOs suggest the greatest health needs include treatment of fever, skin problems, diarrhea and prenatal

care. The successful implementation of a health screening protocol like our proposed study may become a platform to scale up in different migratory routes in the Americas and in other regions. Furthemore, the successful conduction of this study may provide crucial information to increase awareness and lead to effective targeted healthcare services for migrant peoples in transit.

Conclusion

The results of the qualitative and quantitative studies answer the PAHO call to contribute to a better understanding of the health status and health needs of migrant peoples in transit through Panama. It will also serve to strengthen interventions of national and decentralized health and surveillance systems nationally and regionally. Most importatly, the results from this study can be used to develop targeted interventions of healthcare provision for migrant peoples in transit through the DF and the Americas.

Acknowledgments:

We are thankful to the Center for Research and Diagnosis of Emerging and Infectious Diseases, Meteti, Darien of the *Instituto Conmemorativo Gorgas de Estudios de la Salud*, Community Development Network of the Americas, *UNICEF, Médecins Sans Frontières, Panamás Ministerio de Salud, Servicio Nacional de Fronteras* (SENAFRONT) and *Servicio Nacional de Migración* for their ongoing support. We are additionally thankful to those who have contributed thus far to this project: Acino Swiss Farma, Ann Knudson, and the Oklahoma University's Physicians Pharmacy, Sagrav SA, and Omega Diagnostics.

Declaration of conflicting interests:

The authors declare no conflicts of interest.

Funding

Funding is provided by *Instituto Conmemorativo Gorgas de Estudios de la Salud* (Panama), Community Development Network of the Americas, Acino Swiss Farma (donation), Neglected Tropical Diseases Fund and University of Colorado (donation by Mr. Howard Janzen). Additional donations have come from Sagrav SA and Omega Diagnostics, and a large proportion

of the diagnostic tests have been donated through individual research funds from the National Research System (´SNI´ by member Dr. José Antonio Suárez).

Author contributions

Contributor Role	Role Definition
Conceptualization	AG, MJ, JTE, JAS, JMP
Funding Acquisition	AG, FR, JMP, CFP, NAH
Methodology	AG, MJ, JTE, JAS, JP, MB, JS, JK, CN, DB, CGT
Project Administration	AG, FR
Supervision	JMP
Validation	PM
Visualization	AG
Writing – Original Draft Preparation	AG, MJ, JTE, AHM, JMP
Writing – Review & Editing	AG, MJ, JTE, JAS, JP, MB, JS, JK, CN, DB, YZ, AHM, CFP, NAH, MP, FR, NG, JAG, GV, GCT, JMP

ORCID IDs

Amanda Gabster, PhD*	0000-0002-7712-0444
Monica Jhangimal, MD	0000-0002-2470-055X
Jennifer Toller Erausquin, PhD	0000-0003-4271-6077
José Antonio Suárez, MD	0000-0001-9407-1624
Justo Pinzón, MD, MSc	0000-0002-3084-7793
Madeline Baird, MSc	0000-0003-3490-8722
Jennifer Katz, BSc	0000-0003-2686-1071
Davis Beltran, PhD	0000-0003-3183-3753
Gonzalo Cabezas Talavero, MSc	0000-0003-0401-4621

Andrés F. Henao-Martínez, MD	0000-0001-7363-8652
Carlos Franco-Paredes, MD	0000-0001-8757-643X
Nelson I. Agudelo Higuita., MD	0000-0002-9363-6280
Mónica Pachar, PhD	0000-0003-4400-4209
Nathan Gundacker, MD	0000-0002-1614-5824
José Anel González, MD	0000-0003-4285-2298
Fatima Rodriguez	0000-0002-3470-5258
Juan Miguel Pascale, MD, PhD	0000-0003-3258-1359

References

1.   Migration IOf. World Migration Report 2020 2020 [cited 2021 October]. Available from: https://www.un.org/sites/un2.un.org/files/wmr_2020.pdf.

2.   The UN Refugee Agency. Refugee Data Finder 2021 [cited 2021 November]. Available from: https://www.unhcr.org/refugee-statistics/.

3.   UNICEF. The girl who dreamed of pizza in the middle of the world's most dangerous jungle Online2020 [cited 2021 August]. Available from: https://www.unicef.org/panama/historias/girl-who-dreamed-pizza-middle-worlds-most-dangerous-jungle.

4.   Vyas K. Rapes of U.S.-Bound Migrants Make a Treacherous Route Even More Dangerous. The Wall Street Journal. 2021.

5.   Fitzgerald DS. Refuge Beyond Reach How Rich Democracies Repel Asylum Seekers: Oxford University Press; 2019.

6.   Gilman D. Barricading the Border: COVID-19 and the Exclusion of Asylum Seekers at the U.S. Southern Border. Frontiers in Human Dynamics. 2020;2(8).

7.   TVN Noticias. Alrededor de 17 mil migrantes han transitado por Panamá en lo que va del 2021 2021 [cited 2021 junio]. Available from: https://www.tvn-2.com/nacionales/seguridad/Aproximadamente-mil-migrantes-transitado-Panama_0_5869662986.html.

8.   Migración SNd. Estadísticas online2021 [cited 2021 junio]. Available from: https://www.migracion.gob.pa/inicio/estadisticas.

9.   International Organization for Migration. Seguimiento a la emergencia: Septiembre 2020-Febrero 2021 Online: IOM; 2021 [cited 2021 july]. Available from: https://displacement.iom.int/system/tdf/reports/REPORTE%20DE%20SITUACION-%2318-ERMS-COVID%2019%20%281%29.pdf?file=1&type=node&id=11318.

10.   International Migration Organization. Más de 91.000 migrantes han cruzado el Tapón del Darién rumbo a Norteamérica este año 2021 [cited 2021 October]. Available from: https://www.iom.int/es/news/mas-de-91000-migrantes-han-cruzado-el-tapon-del-darien-rumbo-norteamerica-este-ano.

11.   Arcilla Jaramillo O. En 12 años, atravesaron la selva de Darién 188 mil 873 migrantes Online: La Prensa; 2021 [cited 2021 Septiembre]. Available from: https://www.prensa.com/impresa/panorama/en-12-anos-atravesaron-la-selva-de-darien-188-mil-873-migrantes/.

12.   Bensman T. A United Nations of Mass Illegal Immigration, Part 1 2021 [updated June 29, 2021; cited 2021 August]. Available from: https://cis.org/Bensman/United-Nations-Mass-Illegal-Immigration-Part-1.

13.   UNICEF. Fifteen times more children crossing the Panama jungle towards the USA in the last four years 2021 [cited 2021 july]. Available from: https://www.unicef.org/press-releases/fifteen-times-more-children-crossing-panama-jungle-towards-usa-last-four-years.

14.   Pinzón-Espinosa J, Valdés-Florido MJ, Riboldi I, Baysak E, Vieta E. The COVID-19 Pandemic and Mental Health of Refugees, Asylum Seekers, and Migrants. J Affect Disord. 2021;280(Pt A):407-8.

15.   Gabster A, Erausquin JT, Michielsen K, Mayaud P, Pascale JM, Pericas C, et al. How did COVID-19 measures impact sexual behaviour and access to HIV/STI services in Panama? Results from a national cross-sectional online survey. Sexually Transmitted Infections. 2021:sextrans-2021-054985.

16.   Panamerican Health Organization. Guidance document on migration and health Online: PAHO; 2019 [cited 2021 June]. Available from: https://www.paho.org/en/documents/guidance-document-migration-and-health.

17.   Kpokiri EE, Wu D, Srinivas ML, Anderson J, Say L, Kontula O, et al. Development of an international sexual and reproductive health survey instrument: results from a pilot WHO/HRP consultative Delphi process. Sex Transm Infect. 2021.

18.   Alasagheirin MH, Clark MK. Skeletal growth, body composition, and metabolic risk among North Sudanese immigrant children. Public Health Nurs. 2018;35(2):91-9.

19.   Eurostat. European Health Interview Survey (EHIS wave 3)
Methodological manual online: Publications office of the European Union; 2018 [cited 2021 May]. Available from: https://ec.europa.eu/eurostat/documents/3859598/8762193/KS-02-18-240-EN-N.pdf/5fa53ed4-4367-41c4-b3f5-260ced9ff2f6.

20.   Last JM, Adelaide DP. The iceberg: 'completing the clinical picture' in general practice. 1963. Int J Epidemiol. 2013;42(6):1608-13.

21.   Rasmussen S, Søndergaard J, Larsen PV, Balasubramaniam K, Elnegaard S, Svendsen RP, et al. The Danish Symptom Cohort: Questionnaire and Feasibility in the Nationwide Study on Symptom Experience and Healthcare-Seeking among 100 000 Individuals. Int J Family Med. 2014;2014:187280.

22.   Paik A. The Contexts of Sexual Involvement And Concurrent Sexual Partnerships. Perspectives on Sexual and Reproductive Health,. 2010;42(1):33-42.

23.   Gabster A, Pascale JM, Cislaghi B, Francis SC, Weiss HA, Martinez A, et al. High prevalence of sexually transmitted infections, and high-risk sexual behaviours among

indigenous adolescents of the Comarca Ngäbe-Bugle, Panama. Sexually Transmitted Diseases. 2019;46(12):780-7.

24.   Gabster A, Mohammed DY, Arteaga GB, Castillero O, Mojica N, Dyamond J, et al. Correlates of Sexually Transmitted Infections among Adolescents Attending Public High Schools, Panama, 2015. PloS one. 2016;11(9):e0163391.

25.   Condon S, Lieber M, Maillochon F. Feeling Unsafe in Public Places: Understanding Women's Fears. Revue française de sociologie. 2007;48:101-28.

26.   Bellón JA, Delgado A, Luna J, P. L. Cuestionario Apoyo Social Funcional de Duke. Med Care. 1988;26:709-23.

27.   Khaled Fahim N, Negida A. Sample Size Calculation Guide - Part 1: How to Calculate the Sample Size Based on the Prevalence Rate. Adv J Emerg Med. 2018;2(4):e50.

28.   International Organization for Migration. Analysis of Flow Monitoring Surveys Online2019 [updated 2019; cited 2021 August]. Available from: https://dtm.iom.int/reports/panama-—analysis-flow-monitoring-surveys-extrarregional-migrants-june-2019.

29.   Devries KM, Child JC, Elbourne D, Naker D, Heise L. "I never expected that it would happen, coming to ask me such questions":Ethical aspects of asking children about violence in resource poor settings. Trials. 2015;16:516.

30.   Fereday J, Muir-Cochrane E. Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development. International Journal of Qualitative Methods. 2006;5(1):80-92.

31.   The L. Climate migration requires a global response. Lancet. 2020;395(10227):839.

32.   UN Migration. World Migration Report 2020: IOM; 2020 [cited 2021 August]. Available from: https://www.un.org/sites/un2.un.org/files/wmr_2020.pdf.

33.   Morales-Hernandes S. Central American Migrants in Transit through Mexico Women and Gender Violence; Challenges for the Mexican State. Procedia. 2014;161:263-8.

34.   Lemus-Way MC, Johansson, H,. Strengths and Resilience of Migrant Women in Transit: an Analysis of the Narratives of Central American Women in Irregular Transit Through Mexico Towards the USA. Int Migration & Integration. 2020;21:745–63.

35.   Martinez-Donate AP, Verdecias N, Zhang X, Jesús Eduardo GF, Asadi-Gonzalez AA, Guendelman S, et al. Health Profile and Health Care Access of Mexican Migration Flows Traversing the Northern Border of Mexico. Med Care. 2020;58(5):474-82.

36.   Vissandjée B, Short WE, Bates K. Health and legal literacy for migrants: twinned strands woven in the cloth of social justice and the human right to health care. BMC Int Health Hum Rights. 2017;17(1):10.

37.   Panagiotopoulos T. Screening for infectious diseases in newly arrived migrants in Europe: the context matters. Euro Surveill. 2018;23(28).

38.   Jackson J. Drugs, migrants and rebels: Life along Darién's Gap. Al Jazeera. 2015 17 may 2015.

39.   Willen SS, Selim N, Mendenhall E, Lopez MM, Chowdhury SA, Dilger H. Flourishing: migration and health in social context. BMJ Glob Health. 2021;6(Suppl 1).

Map 1: Countries of origin of migrant peoples in transit, after crossing the Darien Forest, Migrant Reception Stations in Darien, Panama (documented from data collected by Migration System, Panama, March 2021).

Table 1: Study components and activities to be undertaken

	Qualitative (Component A)	Quantitative Component B				
	Qualitative data collection	Quantitative questionnaire	Mental Health	Sexual and Reproductive Health	General and Tropical Medicine	Nutrition
Target Population	Community officials, governmental and non-governmental personnel that work with the target population, migrant peoples in transit, people that live in the communities where migrant peoples travel through or live	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit	Migrant peoples in transit
Activities	Semi-structured interviews, focus groups and participant observation	Self-administered quantitative questionnaire	Clinical evaluation and screening	Clinical evaluation and screening	Clinical evaluation and screening	Clinical evaluation and screening

Table 2: Inclusion and exclusion criteria for the study

	Inclusion criteria	Exclusion criterion
Qualitative Study	1. Aged >17 years 2. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	
Quantitative Questionnaire	1. Aged >17 years 2. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	
Mental health	1. Aged >12 years 2. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	Have a planned exit from an MRS the same day the study team has reached the person
Sexual and Reproductive Health	1. Aged >12 years 2. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	
General and Tropical Medicine	1. Speak and write at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	
Nutrition	1. Speak and write, or have a guardian if under 12 that speaks and writes at least basic level one of these languages: Spanish, English, Haitian Creole, French or Portuguese	

Table 3: Study activity, target population, and primary outcomes

	Activity	Target population	Site	Primary outcomes
Qualitative Component	Focus groups	Host communities	Host communities	Effects of migrant presence on communities, health priorities, and needs.
	Semi-structured interviews and participant observation	Migrant peoples in transit	MRS	Migration experience, barriers to health access and existing programs, health needs
	Semi-structured interviews and participant observation	Public institution and non-profit national/international organization leaders who work with migrant populations in transit	MRS, health centers, institutional and organization offices	Health services available, barriers to access, needs of institutions and organizations
Quantitative Component	Self-administered questionnaire	Migrant peoples in transit	MRS	• Sociodemographic and journey information • Human smuggling and trafficking • Education and employment • Self-rated health status • Sexual biography and sexual experience • Female genital cutting (for some countries) • Pregnancy and fertility • Self-reported STI/HIV current and past • Non-consensual sex • Whereabouts of family members and communication with family • Felt social support
	Mental health	Migrant peoples in transit	MRS	• Use of Refugee Health Screener to do an initial screen of PTSD, depression, anxiety, and somatization. • MINI Neuropsychiatric International Interview: Diagnosis by DSM-5 and ICD-10 criteria • EUROHIS Quality of life interview: subjective quality of life
	Sexual and reproductive health	Migrant peoples in transit	MRS	• Screening for vaginal and urethral discharge disease • Screening for genital ulcer disease • Urine dipstick test (leukocyte esterase and nitrite)

			- HIV rapid test (4th generation) - Syphilis rapid test, RPR titer confirmatory
General and tropical medicine	Migrant peoples in transit	MRS	- Rapid point of care tests for: - HAV - HBV - HCV - HEV - Chagas - Malaria - Dengue - Chikungunya - Pregnancy - Further screening based on clinical presentation (Table 4) - Clinical screening: - Review of present and past medical history - Vital signs: Blood pressure, heart rate, respiratory frequency, temperature, blood oxygen saturation - Physical examination based on systems: neurological, cardiovascular, respiratory, gastrointestinal, hepato-splenic, skin, and genitourinary
Nutrition	Migrant peoples in transit	MRS	- Screening for malnutrition and undernourishment - Height-weight - Body Mass Index (BMI) - MUAC - Marasmus and Kwashiorkor screening - MUST - Skinfold test - OMS growth charts

Table 4: Further test based on clinical criteria for inclusion

Test	Clinical Criteria for inclusion
COVID-19 (Antigen or PCR)	Fever or clinical suspicion
Crypto-Giardia-Entamoeba (antigen)	Diarrhea
Cytomegalovirus (antibody)	HIV positive, pregnant women with clinical suspicion
Yellow Fever (PCR)	Fever or clinical suspicion
Amsel Criteria	Vaginal secretion and suspicion of candidiasis
Trypanosoma cruzi detection (Blood smear)	Chagas positive test result, presence of acute symptoms, and suspicion based on country of origin
Leishmaniasis (Tissue Giemsa Stain)	Suggestive ulcer and clinical suspicion
Mycobacterium leprae (Ziehl-Nielsen Stain or Fite-Faraco Stain)	Clinical suspicion of hypochromic anesthetic lesion or nodule
Leptospira (serum IgGIgM antibody)	Fever or clinical suspicion
Malaria- (thick blood smear)	Clinical suspicion and based on country of origin (if endemic)
Rota/adenovirus (Stool antigen)	Pediatric age with diarrhea or gastroenteritis, in adults: fever and symptomatic respiratory
Measles (antibody)	Fever, malaise rash, cough, coryza, conjunctivitis, enanthem, and morbilliform exanthem
TORCH: Toxoplasmosis, Rubeola, CMV, HSV 1 and 2 (antibody)	Pregnant and in 1-month-old babies
Toxoplasmosis (antibody IgG)	HIV positive, pregnancy, and/or clinical suspicion
Tuberculosis (Sputum Bacilloscopic)	Fever, cough, nocturnal sweat, HIV +
Typhus / Para-typhus (Blood antigen)	Fever and clinical suspicion

Table 5: On-site treatment by study subcomponent

Study sub-component	Treatment Given On-Site for Diagnosed Etiology or Based on Clinical and Syndromic Suspicions
Mental Health	
	Distress, psychosis, and/or risk of self or hetero-aggressive outburst: Management with verbal containment and, if needed, pharmacologic management with 5mg of diazepam, repeated up to two times; if not, olanzapine 5mg PO or haloperidol 5mg IM.
Sexual and Reproductive Health	
	1. Genital Herpes simplex: Acyclovir 400mg PO TID for seven days. 2. Recurrent genital Herpes Simplex: Acyclovir 800mg PO TID for 2 days or 400mg PO TID for 5 days. 3. Syphilis: Benzathine Penicillin 2.4 million UI single-dose IM , once or each conceccutive week for three weeks depending on patient history/RPR 4. Syphilis in pregnant women: 2.4 million IU IM each week for 3 weeks 5. Chancroid: Azithromycin 1g PO single dose OR Ceftriaxone 250mg single dose IM OR Ciprofloxacin 500mg bid for 3 days 6. Chancroid in pregnant/lactating women: Erythromycin 500mg PO QID for 15 days 7. *Lymphogranuloma venerum*: Doxycycline 100mg PO daily for 21 days OR Erythromycin 500mg PO QID for 21 days OR Azithromycin 1g PO each week for 3 weeks 8. *Neisseria gonorrhoeae*: Ceftriaxone 500mg IM single dose 9. *Chlamydia* trachomatis: Azithromycin 1g PO single dose or Doxycycline 100mg PO bid for 7 days. 10. *Trichomonas vaginalis*: Metronidazole 2g PO single dose 11. *Candida albicans*: Fluconazole 150mg PO single dose OR Clotrimazole ovules 100mg intravaginal for 7 days 12. Bacterial vaginosis: Metronidazole 2g PO single dose
General and Tropical Medicine	
	1. Cardiovascular system: Symptoms associated with myocarditis, endocarditis, pericarditis with clinical suspicion of: 1.1 Mild leptospirosis: Doxycycline 100mg PO bid for 7 days OR Azithromycin 500mg PO each day for 3 days 1.2 *Trypanosoma cruzi*: Benznidazole 5-7mg/kg/day PO divided in two doses: bid for 60 days 1.3 *Taenia solium*: Praziquantel 10mg/kg PO single dose 1.4 *Ascaris lumbricoides*: 400mg PO single dose 1.5 *Strongyloides stercolaris*: Ivermectin 200 µg/kg/day PO for 1- 2 days 1.6 *Paragonimus westermanii*: Praziquantel 25mg/kg PO tid for 2 days 1.7 *Mansonella perstans*: Doxycycline 200mg PO each day or 100mg PO bid for 6 weeks 2. Congestive Heart Failure symptoms that might be due to:

2.1 *Schistosoma mansonii*: Praziquantel 40mg/kg PO single dose

3. Loeffler Syndrome that might be due to:
3.1 *Ascaris lumbricoides*: Albendazole 400mg PO single Dose
3.2 *Strongyloides stercolaris*: Ivermectin 200 µg/kg/day PO for 1- 2 days
3.3 *Ancyslostoma duodenale*: Albendazole 400mg PO for 1-3 days
3.4 *Necator americanus*: Albendazole 400mg PO for 1-3 days

4. Dyspnea or Pneumonia suspicion due to:
4.1 *Streptococcus pneumoniae*:
- With recent use of antibiotics and comorbidities: Amoxicillin-Clavulanate 875/125mg- 1 tablet PO bid + Clarithromycin 500mg PO bid for 7 days OR Azithromycin 500mg PO in the first dose and then 250mg PO each day for 4 days
- With recent use of antibiotics and no comorbidities: Amoxicillin 1g PO bid for 7 days
- -No recent use of antibiotics: Clarithromycin 500mg PO bid for 7 days or Azithromycin 500mg PO in the first dose and then 250mg PO each day for 4 days.

4.2 *Mycoplasma pneumoniae* / *Chlamydia pneumoniae* / *Chlamydia psittaci*: Doxycycline 100mg PO bid for 7 days
4.3 *Haemophilus influenzae*: Amoxicillin/Clavulanate 875/125mg tab one tablet PO bid for 7 days.
4.4 Legionellosis: Levofloxacin 750mg PO each day for 10 days
4.5 Coccidioidomycosis: Fluconazole 400mg PO each day for 3-12 months
4.6 Blastomycosis: Itraconazole 200mg PO tid for 3 days and then each day for 6-12 months
4.7 *Schistosoma mansonii*: Praziquantel 40mg/kg PO single dose
4.8 Filariasis: Doxycycline 100mg PO each day for 6-8 weeks

5. Gastrointestinal symptoms- Hepato-splenomegaly by clinical diagnosis or suspicion of the following etiologies:

5.1 *Schistosoma mansonii* / *japonicum*: Praziquantel 40mg/kg-60mg/kg PO single dose (without previous treatment, dependent on country of origin) Suspiacian of acute toxemic shistosomiasis: short corse high-dose prednisone + 40mg/kg-60mg/kg Praziquantel PO in single dose, repeat Praziquantel in 4-6 weeks.

5.2 Toxocariosis: Albendazole 400mg PO bid for 5 days + Prednisone (optional) 60mg each day for 5 days

Jaundice (pre-hepatic-post) by clinical diagnosis or suspicion of the following etiologies:

5.3 *Bartonella bacilliformis*: Doxycycline 100mg PO each day for 6-8 weeks
5.4 *Coxiella burnetti*: Doxycycline 100mg PO each day for 2 weeks
5.5 *Chlamydia psittaci*: Doxycycline 100mg PO each day for 7 days
5.6 *Salmonella typhi*: Levofloxacin 750mg PO each day for 7 days
5.7 *Ascaris lumbricoides*: Albendazole 400mg PO single dose (may also be related to malabsorption syndrome)
5.8 *Cryptosporidium parvum/hominis*: Nitazoxanide 500mg PO bid for 3 days

	5.9 *Giardia lamblia*: Tinidazole 2g PO single dose (may also be related to malabsorption syndrome) 5.10 *Strongyloides stercolaris*: Ivermectin 200µg/kg/day for 1-2 days 5.11 Trichinellosis: Albendazole 400mg bid for 8-14 days + Prednisone 60mg PO each day
	6. Cutaneous- by papule / macule (vascular or not painful) 6.1 *Bartonella henselae/bacilliformis:* Doxycycline 100mg PO each day for 7 days 6.2 Human Papillomavirus: Podofilox gel or solution at 0.5% - apply tid for 30 days 6.3 *Molluscum contagiosum*: Amphotericin B 0.6mg/kg/day PO for 2 weeks OR Itraconazole 400mg/day PO for 10 weeks and then 200mg/day PO till the CD4 count in HIV patients is >100cells /µL for >6 months responding to RVT By papule/macule (painful) 6.4 *Dermatobia hominis / Cordylobia anthropophaga / Tunga penetrans:* Petroleum jelly or an occlusive agent so when the larva moves, a manual extraction is done. By papule/macule that causes itch 6.5 *Schistosoma* spp: Praziquantel 40mg/kg single dose PO 6.6 *Pediculus humanus corporis/capitis*: Ivermectin 12mg PO each day for 14 days 6.7 *Sarcoptes scabiei*: Permethrin cream 5% apply on skin for 8-14 hours and repeat in 1-2 weeks Vesicles 6.8 Herpes simplex virus 1 and 2 : Acyclovir 400mg PO tid for 7-10 days 6.9 Sporotrichosis: Itraconazole 200mg PO each day for 2-4 weeks 6.10 *Rickettsia akari/prowazekii/typhi* / Leptospirosis: Doxycycline100mg PO bid for 7 days 6.11 *Borrelia burgdorferi*: Doxycycline 100mg PO bid for 2 weeks Morbilliform exantem 6.12 *Mycoplasma pneumoniae*: Doxycycline 100mg PO bid for 7 days 6.13 *Ehrlichia chafeensis / Anaplasma phagocytophilum* 100mg PO bid for 2 weeks 6.14 *Histoplasma capsulatum*: Itraconazole 200mg TID for 3 days, then 200mg bid for 12 months 6.15 *Coccidioides posadasii*: Fluconazole 400mg PO each day for 3-12months 6.16 *Sporothrix* spp.: Itraconazole 200mg PO each day for 2-4 weeks 6.17 Actinomycetoma: Itraconazole 200mg PO each day for 2-4 weeks 6.18 Chromoblastomycosis (*Fonsacaea pedrosoi*): Itraconazole 300mg PO each day for 3-9 months
Nutrition	

	Mild-moderate acute malnutrition in: -Children from 0 to 6 months -Children from 6 months to 5 years -Children 6-17 years old -18 years or above: Men and women -Pregnant women

Supplementary material A: Self applied questionnaire (English version, however questionnaire will also be available in Spanish, Haitian Creole, French and Portuguese). Note: this questionnaire will be self-applied on a tablet, therefore the format will differ and conditioned questions will only only appear if they apply. This questionnaire was developed from existing surveys and modified for migrant peoples in transit through the Darien Forest, Panama (17-26).

		Question	Possible responses	Conditions
Question number		Participant code	xxx	
A1	Sociodemographics and journey information	How old were you at your last birthday?	_________ years	
A2		At birth, were you described as….?	a. Male b. Female c. Intersex, undetermined or another sex	
A3		Today, do you think of yourself as…?	a. Man/boy b. Wom/girl c. In another way	
A3a		Please describe how you describe yourself ´in another way´	_________________	if answer c above
A4		What is your mother tongue (language you were raised in), you can answer more than one	_________	
A5		What country were you born in?	_________ country (drop down menu)	
		In this survey, we will refer to the country of origin as were you started your journey from, and the country of residence as an intermediary country that you stopped in for some time (6 months or more) before continuing on		
A6		Did you reside in a different country (for more than 6 months) after you left your country of origin?	a. No b. Yes	
A7		What is the last country you lived in where you resided (had lived continously for at least 6 months)?	_________ country	if answered b above
A8		When you left the last country of residence, what countries have you travelled through or lived in? Please list all countries	_______________	
A9		What country do you want to stop travelling in (what is your country of destination	_________________ (type I dont want to answer if you do not want to answer)	

A10		In the past month, did you have a safe place to sleep at night?	a. I have never had a safe place to stay b. I sometimes had a safe place to stay c. I always had a safe place to stay	
A11		In the past month, do you feel like you and your family who you travel with had enough access to food?	a. No, I always felt we needed more food than we had b. At times we had enough food, but other times we needed more c. Yes, we always had enough food during the past month	
A12		In the past month, did you or a family member you are travelling with ever cut the size of your meals or skip a meal because there was not enough food?	a. No b. Yes	
A13		In the past month, do you feel like you and your family who you are traveling with had enough clean water to drink?	a. No, I always felt we needed more clean water than we had b. At times we had enough clean water, but other times we needed more c. Yes, we always had enough clean water during the past month	
A14		What is the main reason why you are travelling? (please answer all that apply)	a. War or conflict b. Other violence c. work d. family e. poverty f. Another reason	
A14a		What is the other reason?	________________	if f answered to A11
A15		Since you started arrived in Panama, including before crossing the Darien Gap and while crossing the Darien Gap, did you wear shoes while travelling? (shoes include flip flops, sandals, runners or boots)	a. No, I did not have shoes at all b. I had shoes part of the time while travelling c. I had shoes during the whole time	
A16	Human smuggling questions	What is the total cost of your travel (and your family´s travel, if travling with you) since leaving your country of origin?	____________ dolares	

A17		Did you borrow money in order to make this trip?	a. No b. Yes	
A18		Have you been pressured to do anything you didn't want to do to pay it back?	a. No b. Yes	if b on A18
A19		Sometimes people do unfair, unsafe, or even dangerous work or stay in dangerous situations because if they don't, someone might hurt them or someone they love. Since leaving your country of origin, has anyone you know, (including yourself) ever experienced this?	a. No b. Yes c. Declined to answer d. Don´t know	
A20		Sometimes people are not allowed to keep or hold on to their own identification or travel documents. Since leaving your country of origin, has anyone you know (including yourself) ever epxerienced this?	a. No b. Yes c. Declined to answer d. Don´t know	
A21		Many people who travel to North America find themselves in harsh working conditions. Since leaving your country of origin, has anyone you know (including yourself) ever worked or done something that you/they thought there would be payment for, but were not paid?	a. No b. Yes c. Declined to answer d. Don´t know	
A22		Many people who have traveled to North America have seen others who are traveling participate in a range of different activies. Since you left your country of origin, has anyone you know (including yourself) been in any of the following situations?	a. Given work/employment but not given enough food, a place to sleep or working conditions that they were comfortable with. b. Felt forced into undertaking sexual services including participating in sexual activites and/or having sexual photos/videos taken	

			illegal activities, including carrying drugs, participating in robbery, or any other illigeal activity d. Felt forced by someone into begging for money and the money went to that person. e. None of the events above have happened to me or another person I know while traveling.	
A23		Sometimes people pay others with money, things or sex to help them enter another country. Since you left your country of origin, has anyone you know (including yourself) ever been in a situation like this?	a. No b. Yes c. Declined to answer d. Don´t know	
A24		Would you like to talk to someone (a member of our study team or someone at the local health centre) about the event you listed above that you or the people you know experienced?	a. No b. Yes	
A25	Education and employment	What is the highest level of education you have completed	a. I have never had formal education b. grades 1-6 (primary school in many countries) c. 7-12 grades (Secondary school in many countries) d. Post-secondary level (above grade 12, trade school, university, masters or doctoral level)	
A26		In the last country you resided in for an extended period of time (6 months),	a. No b. Yes	

		employment?		
A26a		What was this employment?	___________________	if yes to B2
B1	Self-rated health	In general, would you say your health is:	a Excellent b. Very good c. Good d. fair e. poor	
B2		Compared to one year ago, how would you rate your health in general now?	a. Better now than one year ago b. About the same now than one year ago c. Worse now than one year ago	
B3		How much bodily pain have you had during the past 4 weeks?	a. None b. Very mild c. Mild d. Moderate e. Severe f. Very Severe	
B4		During the past 4 weeks, how much did pain interfere with your normal life?	a. Not at all b. A little bit c. Moderately d. Quite a bit e. Extremely	
B5		Since you arrived in Panama, including before crossing the Darien Gap, while crossing the Darien Gap and while in the Migrant Station, Have you had any of these symptoms? Please mark all symptoms you´ve had..	Tiredness	
			Night-time urination	
			Lack of energy	
			Headache	
			Back pain	
			Abdominal bloating	
			Memory problems	
			Abdominal pain	
			Erectile dysfunction	marked a in A2
			Coughing	

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

				Concentration problems	
				Change in stool texture	
				Dizziness	
				Pelvic pain	marked b in A2
				Feeling unwell	
				Constipation	
				Increase in waist circumference	
				Change in stool frequency	
				Diarrhoea	
				Nausea	
				Swollen legs	
				Difficulty in emptying the bladder	
				Frequent urination	
				Pelvic pain during intercourse	marked b in A2
				Stress incontinence	
				Shortness of breath	
				Hoarseness	
				Urge incontinence	
				Loss of appetite	
				Blood in stool/rectal bleeding	
				Fever	
				Difficulty swallowing	
				Weight loss	
				Vaginal bleeding after intercourse	marked b in A2
				Incontinence without stress/urge	
				Postmenopausal bleedinga	marked b in A2
				Pain/burning when urinating	
				Lump/swollen lymph nodes	
				Black stool	
				Repeated vomiting	
				Blood in urine	
				Blood in semen	Marco a en A2

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

			Coughing up blood	
			Blood in vomit	
B5a		What did you do with _______ symptom, please mark all that you did	a. I did nothing b. I treated it myself at home c. A traditional/ botanical doctor treated me d. A Western doctor (health center hospital) treated me	Asked of every symptom marked above
C1	Sexual biography and sexual experience	Are you at present…	a. Single b. Married. c. living with someone as a couple but not married d. Separated but still legally married e. divorced. F. widowed	
C3		How many times have you been married or lived together with someone as a couple?	____ times	
C4		How old were you when you first started living with a partner or spouse?	____years	
		This next section asks questions about sex. By 'sex', we mean any sexual contact involving the genital area, including oral sex, vaginal sex, anal sex		
C5		In your lifetime, have you at any time engaged in sex with:, please check all that apply (C5-C7 table question format)	a. Only men b. Only women c. Men and women d. Transmen e. Transwomen f. No one	
C6		Since you left your last country of residence, but before arriving in Panama, did you at any time engage in sex with: please check all that apply	a. Only men b. Only women c. Men and women d. Transmen e. Transwomen f. No one	
C7		Since you left your last country of residence, how many different people have you had sex with? .Please include everyone you have ever had sex with, whether it was just once or multiple times, with a stranger, regular partner, or husband/wife.	____number	

C8		Since you´ve arrived in Panama (before or during your walk through Darien Gap and in the migrant stations), at any time with a person who you knew or did not know, did you have sexual experience with (please check all that apply)	a. Only men b. Only women c. Men and women d. Transmen e. Transwomen f. No one	
C8a		Since you arrived in Panama (before and during your walk throught he Darien Gap and in the ERM), how many different people have you had sex with? Please include everyone you have ever had sex with, whether it was just once or multiple times, with a stranger, regular partner, or husband/wife.	______number	if answered a-e to the question above
		The next questions are about the partners you may have or have had and sex you may have had with someone who is not your partner. A partner is one who you were romantically or affectively in a relationship with for 2 weeks or more. Remember, when we talk about sex, we refer to genital contact by vaginal, oral or anal sex		
C9		Have you ever been in a relationship and had sex with another person (not your partner) while you were in the relationship? This sexual encounter could be with someone you knew or didn´t know	a. No b. Yes	
C9a		When have you had sex with someone who is not your partner, while being in a relationship (please mark all that apply)? This sexual encounter could be with someone you knew or didn´t know.	a. Before leaving country of origin b. In transit to a country of residence or Panama c. In a country of residence d. While in Panama (while crossing the Darien Gap or while in an ERM)	if answered a above
C9b		The last time you had sex with someone who wasn´t your partner, while in a relationship, did you use a condom?	a. No b. Part way through the act c. during the whole act	if answered a to C9

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

C10		Have you ever been in a relationship and YOUR PARTNER had sex with another person while you were in the relationship with them?	a. No b. Yes	
C10a		When was it that YOUR PARTNER had sex with someone while being in a relationship with YOU (please mark all that apply)	a. Before leaving country of origin b. In transit to a country of residence or Panama c. In a country of residence d. While in Panama (while crossing the Darien Gap or while in an ERM)	if answered a above
C11		In the last 4 weeks, how many people have you had sex with? Please include everyone you have ever had sex with, whether it was just once or multiple times, with a stranger, regular partner, or husband/wife.	___number	only asked of those who reported a-e in E-5
C11		Did you use a condom in the past 4 weeks when you have had sex?	a. No b. With some partners only c. Yes, with the one or with all the partner(s) I´ve had sex with in the past 4 weeks.	if number is >0
C12		What was your relationship with these sex partner(s)? (please check all that apply)	a. A stranger b. regular sex partner c. husband/wife d. a friend or travel companion e. a person of authority (for example, a politicion, community leader, police person) f. a sex worker g. another person	if answered >0 above, ask
C12a		Can you tell me what relationship this other person had with you?	____________________	if answered g above
		The next section is about situations when sex is exchanged for goods, services, or money. By material goods, we mean things like food, rent, clothes/shoes/cell phones, cosmetics, transport, good marks in school or school fees, or items for your children, your family, or yourself.		

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

C13		When, if ever, was the last time you gave money, material goods, favours, gifts, drugs, or shelter in exchange for sex? (please check all that apply)	a. Before leaving my last country of residence b. After leaving my last country of residence c. Since arriving in Panama d.both before leaving and during my travels after leaving my last country of residence e. Never	
C14		When, if ever, was the last time you received money, material goods, favours, gifts, drugs, or shelter in exchange for sex?	a. Before leaving my last country of residence b. After leaving my last country of residence c. Since arriving in Panama d.both before leaving and during my travels after leaving my last country of residence e. Never	
C15		The last time you had sex (anal sex or vaginal sex) did you use a condom?	a. No, I didn´t use a condom with my casual (non-long term) partner b. No, I don´t use condoms with my long-term partners c. Yes, I used a condom with my casual (non-long-term partner) d. Yes, I used a condom with my long-term partner	
C16		In the past month, did you acquire condoms (as in, were you given or did you purchase condoms)	a. No b. Yes, I purchased them at a store or pharmacy c. Yes, an organization donate or gave them to me	
C17		Do you feel that your journey (since leaving your country of origin or your last country of residnce) has made it more difficult to access condoms when you needed them?	a. No b. yes c. Does not apply because I don´t use condoms	

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

D1	Female genital cutting (only ask question if participant was born in: India, Indonesia, Malaysia, Pakistan and	Have you been cut? By cut we mean female circumcision or the cutting of some or all of your clitoris to any degree.	a. yes b. no	if answered b to A2
D2	Sri Lanka, Oman, United Arab Emirates, Yemen, Iraq, Iran, State of Palestine, georgia, federación Rusa, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Cote d'Ivoire, Democratic Republic of Congo, Djibouti, Egypt, Eritrea, Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Somalia, Sudan, Tanzania, Togo, Uganda and Zambia)	Did you or would you cut your daughter?	a. I have a daughter and she has been cut b. I have a daughter but she has not been cut c. I do not yet have a daughter but if/when I do, I would like for her to be cut d. I do not yet have a daughter but if/when I do, I would not like for her to be cut	if answered b to A2
	Pregnancy and fertility	The next section asks about pregnancy		
E1a		To the best of your knowledge, how many times have you been pregnant to date?	____ veces, type 99if you dont know	responded 'B' to A2
E1b		To the best of your knowledge, how many times have you gotten a woman pregnant to date?	____ veces, type 99if you dont know	Responded 'A' to A2
E2a		How old were you at the time of your first pregnancy (including any pregnancies that did not result in a live birth)? (age at the end of the pregnancy)	____ years, 99 if you don´t know your age	Responded 'B' to A2
E2b		How old were you the first time you got a woman pregnant (including any pregnancies that did not result in a live birth)? (age at the end of the pregnancy)	____years, 99 if you don´t know	Responded 'A' to A2]
E3		How many children do you have that are alive today?	_______	

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

		The next questions are about your age at the end of the pregnancy		
E5A		How old were you at the time of your last pregnancy (including any pregnancies that did not result in a live birth)? (age at the end of the pregnancy)	_____years, 99 if you don´t know	[to participants responding 'B' to A2]
E5B		How old were you the last time you got a woman pregnant (including any pregnancies that did not result in a live birth)? (age at the end of the pregnancy)	_____years, 99 if you don´t know	[to participants responding 'A' to A2]
E6		In the last month, did you or your partner use any of the following to protect against pregnancy or HIV/STIs? (contraceptives)	a. No precautions b. Male condom c. Oral contraceptive pill/injectable contraceptives d. Morning after pill e. IUD/coil/loop f. Cap/Diaphragm g. Spermicides h. my partner withdrew / I withdrew i.made sure it was a safe period in my (or my partner´s) monthly cycle j. my partner or I have been sterilized k. another method of protection l. I don´t know	
		Now we will ask you about the pregnancies you mentioned earlier:		If answered b to A2 and one or more pregnancies to C5
E7		Are you currently pregnant?	a. No b. Yes	If answered b to A2 and one or more pregnancies to C5
E8		How many months are you pregnant	__________ months, type 99 if you do not know	If answered a to C8
E9		Have you ever had a time lasting 1 year or longer when you and your partner were trying to get pregnant and it did not happen?	a. No b. Yes	Ask of everyone

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

	HIV/STI	These following questions ask about the human immunodeficiency virus, also known as 'HIV' the virus that causes AIDS. They also ask about sexually transmitted infections, also known as STIs. As a reminder, you do not need to share any information if you do not want to.		
F1		When, if ever, were you last tested for HIV?	a. In the Last year b. More than 1 year ago. c. Never d. Don´t know e. Prefer not to say	
F1a		What was the result of your last HIV test?	a. I have HIV b. I do not have HIV c. I don´t know d. I prefer not to say	
F1b		Since you started your journey, how often do you take your antiretroviral treatment (ART)?	a. I have never taken antiretroviral therapy b. I stopped taking it before leaving my last country of residence or country of origin c. I take my antirretroviral therapy only sometimes d. I always take my antirretroviral therapy daily	If answered a in F1a
F1c		Since you started your journey, have you ever felt worried that you would not be able to find your antriretroviral treatment?	a. No b. Yes	
F2		In the last month, have you had any of these symptoms? Please mark all that apply	a. Unusual discharge from the penis or vagina b. sores or warts on the genital area c. painful or frequent urination d. itching and redness in the genital area e. abnormal vaginal odor f. anal itching, soreness or bleeding g. abdominal pain h. enlarged lympnodes in the groin area i. None of the above symptoms	
F3		Aside from HIV, when, if ever, have you received treatment for a STI (e.g. gonorrhoea, chlamydia, syphilis, herpes, trichomoniasis) either self-	a. In the last year b. More than 1 year ago. c. Never d. Don´t know e. Prefer not to say	

		from a doctor?		
	Non-consensual sex	These next question is about non-consensual sexual situations that you may have encountered. We understand that these are sometimes difficult to think/talk about, and you can skip any questions you feel uncomfortable answering. Please tell study personnel if you would like to report any abusive relationship or event or if you would like to speak with someone from our team about what happened to you.		
G1		Before leaving on your last country of residence, in your everyday life (at work, on the street, at home) how safe did you feel from sexual assault?	a. Not at all safe b. Somewhat unsafe c. Neither safe or unsafe d. Completely safe e. It varies by the situation	
G2		Since you left your last country of residence, in your everyday life (i.e., in different countries, at the camps, on the trails, rivers, and other spaces), how safe do you feel from sexual assault?	a. Not at all safe b. Somewhat unsafe c. Neither safe or unsafe d. Completely safe e. It varies by the situation	
G3		Since you arrived in Panama (before and during walking through the Darien Gap and in the Migrant Station), how safe have you felt from sexual assault?	a. Not at all safe b. Somewhat unsafe c. Neither safe or unsafe d. Completely safe e. It varies	
G4		In your lifetime, had you ever been forced or frightened by another person into doing something sexually that you did not want to do?	a. Yes, more than one time b. Yes, once c. No, this has not happened to me d. Don´t know/cannot remember e. I prefer not to say	
G4a		How old were you the first time this happened?	_____ years, please type 99 if you do not want to answer	if a or b to the question above
G5		When did this occur (please mark all that apply)	a. Before leaving my country of origin b. In another country of residence c. In transit to Panama d. While in Panama (on the trail or at an ERM) e. I prefer not to say	if answered a or b to G4

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

		Just now, you marked that before leaving your country of origin you had been forced or frightened by someone into doing something sexually you did not want to, What is your relationsip to this person?	a. I do not know who they are b. They are a friend or acquaintance c. They are my formal partner d. I do not want to say	if marked a to G5
		Just now, you marked that while living in another country of residence, you had been forced or frightened by someone into doing something sexually you did not want to, What is your relationsip to this person?	a. I do not know who they are b. They are a friend or acquaintance c. They are my formal partner d. I do not want to say	if marked b to G5
G6		Just now, you marked that in transit to Panama, you had been forced or frightened by someone into doing something sexually you did not want to, What is your relationsip to this person?	a. I do not know who they are b. They are a friend or acquaintance c. They are my formal partner d. I do not want to say	if marked c to G5
G6a		Just now, you marked that while in Panama, you had been forced or frightened by someone into doing something sexually you did not want to, What is your relationsip to this person?	a. I do not know who they are b. They are a friend or acquaintance c. They are my formal partner d. I do not want to say	if marked d to G5
G6b		Did you report this event to an authority (police, non-profit organization, doctor or another person)?	a. No b. Yes	if d to G5
G6c		Would you like to talk to someone (a member of our study team or someone at the local health centre) about the event you experienced?	a. No b. Yes	if marked a, b, c, or d to G5
	The following questions are about your communication with your family members, please remember this information is confidential, however you do not have to answer the questions if it makes you uncomfortable			

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

H1	Whereabouts of family members and communication	Who are you travelling with? Mark all that apply	a. Spouse or partner b. Children c. Parent or grandparent d. other family members (aunt, uncle, niece, nephew) e. a friend or acquantiance f. Another person	
H1a		Who is the other person?	________________	if answered f to the quesiton above
H2		Are there other family members in countries other than Panama you are in contact with (Family members can be spouse, children, parents, or any other member of your family or close friends)	a. No b. Yes	
H2a		What relationship do you have with this person you mentioned above who you are in contact with?	a. Spouse or partner b. Children c. Parent or grandparent d. other family members (aunt, uncle, niece, nephew) e. a friend or acquantiance f. Another person	if b to question above
H3		Are there other family members in countries other than Panama you wish you could have contact with but do not know where they are or have lost contact? (Family members can be spouse, children, parents, or any other member of your family or close friends)	a. No b. Yes	
H3a		What relationship do you have with this person you mentioned above who you have lost contact with?	a. Spouse or partner b. Children c. Parent or grandparent d. other family members (aunt, uncle, niece, nephew) e. a friend or acquantiance f. Another person	if b to question above
	Social support	The following frases are related to your social life and affective support that you receive from other people. Please respond how you currently feel:		

I1		You receive praise and recognition when you do something well	a. None b. Some d. A lot	
I2		You have people near you that are worried about things that happen to you	a. None b. Some d. A lot	
I3		You receive love and affection	a. None b. Some d. A lot	
I4		You have the possibility of talking with someone about problems you have	a. None b. Some d. A lot	
I5		You receive useful advice from someone when something important happens in your life	a. None b. Some d. A lot	
I6		You receive help when you are sick or ill	a. None b. Some d. A lot	

This questionnaire was created by the Gorgas Memorial Institute for Health Studies, 2021

Supplementary material B: Causes for referral to primary, secondary and tertiary centers.

Study component	Motive for Referral
Quantitative Questionnaire	
	Ongoing distress
Mental health	
	Ongoing distress, psychosis and / or risk of self or hetero-aggressive outburst
Sexual and Reproductive Health	
	1. Reported violence: by time since violence occurred and if PEP is possible and support is needed 2. HIV positive: refer if had 6 months or more of continuous treatment prior to study and would like to continue treatment; otherwise receive prophylaxis for AIDS-related opportunistic infections. 3. Syphilis positive- If congenital syphilis is suspected, if the patient is a kid with <30kg of weight or lactating. 4. Pelvic inflammatory disease: Severity symptoms such as fever, nausea, severe abdominal pain; if associated with a pelvic abscess or pregnancy
Pregnancy	5. Early pregnancy bleeding (first trimester): 5.1 Threatened abortion 5.2 Ectopic pregnancy 5.3 Gestational trophoblastic disease 5.4 Pregnancy loss
	6. Second and third trimester bleeding: 6.1 Placenta previa 6.2 Placental abruption 6.3 Pregnancy loss
	7. Complications in the duration of pregnancy 7.1 Pre-term labour 7.2 Pre-term membrane rupture 7.3 Post-term pregnancy
	8. Hypertensive disorders in pregnancy
	9. Post-partum hemorrhage
	10. Infections during pregnancy 10.1 Hepatitis B 10.2 Toxoplasmosis 10.3 Tuberculosis 10.4 Genital herpes 10.5 HIV 10.6 Sepsis
	11. Mental health disturbances associated to pregnancy: 11.1 Postpartum depression 11.2 Perinatal dwelling

General and Tropical Medicine	
	7. Neurological symptoms independent of etiology: meningism signs, polyneuropathy, acute flaccid paralysis, convulsions, autonomic symptoms.
	8. Cardiovascular system: Symptoms associated to myocarditis, endocarditis, pericarditis with clinical suspicion of: 8.1 Diphtheria *8.2 Neisseria meningitidis* *8.3 Coxiella burnetii* *8.4 Mycobacterium tuberculosis* 8.5 Severe leptospirosis 8.6 West Nile river fever 8.7 Yellow fever 8.8 HIV
	9. Congestive Heart Failure symptoms that might be due to: 9.1 Acute rheumatic fever 9.2 Acute Chagas disease 9.3 Wet Beriberi 9.4 Anemia
	10. Stroke: by symptoms or clinical suspicion of: 10.1 HIV *10.2 Toxoplasma gondii* 10.3 Syphilis 10.4 Echinococcosis
	11. Cough by symptoms or clinical suspicion of: 11.1 Brucellosis *11.2 Mycobacterium tuberculosis* *11.3 Coxiella burnetii* *11.4 Bordetella pertussis* 11.5 Lassa fever 11.6 Hantavirus 11.7 COVID-19
	12. Pneumonia clinically diagnosed or suspicion of the following etiologies: 12.1 Aspergillosis 12.2 Histoplasmosis *12.3 Burkholderia pseudomallei* 12.4 Influenza *12.5 Pneumocystis jirovecii*
	13. Hemoptysis- Clinical diagnose or suspicion of the following etiologies: *13.1 Yersinia pestis* *13.2 Mycobacterium tuberculosis* *13.3 Mycobacterium abscessus* *13.4 Staphylococcus aureus* *13.5 Meliodosis/ Burkholderia pseudomallei* *13.6 Paragonimus westermanii*

	14. Pneumonia by vaccine-prevented etiologies
	15. Hepato-splenomegaly- with high suspicion of the following etiologies: *15.1 Mycobacterium tuberculosis* 15.2 Hepatitis virus A,B,C,D,E 15.3 Malaria 15.4 Visceral Leishmania 15.5 Congenital *Trypanosoma cruzi* *15.6 Histoplasma capsulatum*
	16. Ictericia- with suspicion or diagnosis of the following etiologies: *16.1 Schistosoma japonicum / mansoni* 16.2 Malaria 16.3 Babesiosis 16.4 Hepatitis virus A,B,C,D, E 16.5 Dengue virus 16.6 Yellow fever 16.7 Rift Valley fever *16.8 Coxiella burnetii* 16.9 Brucellosis *16.10 Mycobacterium tuberculosis*
	17. Severe dehydration secondary to diarrhea or dysentery
	18. Cutaneous affectations secondary to: *18.1 Mycobacterium leprae* *18.2 Mycobacterium tuberculosis* *18.3 Mycobacterium abscessus* *18.4 Mycobacterium ulcerans* *18.5 Corynebacterium diphtheria* 18.6 Leishmaniasis *18.7 Neisseria meningitidis* 18.8 Ebola/Marburg 18.9 Dengue virus 18.10 Chikungunya 18.11 Rubeola 18.12 HIV/Acute Retroviral Symptoms 18.13 Measles 18.14 West Nile Virus
Nutrition	
	Severe acute malnutrition in: -Children from 0 to 6 months -Children from 6 months to 5 years -Children 6-17 years old -18 years or above: Men and women -Pregnant women

Supplementary Material C: Distress protocol

The distress protocol will be filled out by the researcher or field assistant involved in the identification of the distress. The following questions will be answered, and if if the response is yes on any, the situation will be reported to the principal investigator.

Questions to ask of the participant in a state of distress (circle one)
- Did the participant show signs of distress related to a part of the study (partner violence, sexual violence, any other kind of violence or another topic in the study?) **Yes / No**
- Did the participant have to abandon the study due to the distress? **Yes / No**
- Did the participant report a situation of violence (intimate partner or another)? **Yes / No**
- Did or does the participant presenta acute psychosis and or an elevated risk of self o hetero agression? **Yes / No**

If the participant answered yes to any of these questions, please find the PI or the co-investigator in charge.

To be explained to the participant: "we would like to support all participant who present with distress of any kind. Do you have any questions about the study?"

Directions after a "yes" was received to the answers above
1. Take the participant to a safe place and ask how they feel
2. Listen to the participant. If they share something, listen with empathy to whatever they want to share.
3. Invite the participant to meet again with you at a specific time, within a couple hours.
4. If the participant comes to the meeting, ask how they are feeling.
5. If the participant is still in a distressed state, or a psychotic break or a situation of increased risk of self or retrogression, they should be taken for an evaluation with the study psychiatrist, who will evaluate if the individual needs further assistance through a referral.

Supplementary material D:
Management of individuals who report sexual violence
If sexual violence has been reported, Ministry of Health authorities will be contacted discreetly; the decisión to contact the authorities will be made by the PI or another co-investigator who is in charge.

The table below indicates where and with what urgency the reference to the Ministry of Health or should be made.   These are based on the Ministry of Health (MOH) procedure for sexual violence, rape, incest, and a previously published protocol for children who report violence *(29)*.

The participant reports	urgency of the referral	Reported incident	Referral to	Time to undertake the response and referral
Level 1: Forced sexual intercourse, or severe sexual violence in the last 72 hours	Urgent	In the last 72 hours, they have been forced to have sex	Referral and accompaniment to MOH personnel	Within 6 hours of the incident report.
Level 2: Severe sexual violence between 3 to 14 days, and minor sexual violence, or if it is more than a week, but the person was in Panamanian territory.	Less urgent, but with notification	Between 3-14 days, the violence occurred. Or, at any time, some less severe act: someone touched their genitals, breasts, or buttocks; forced to touch the genitals, breasts, or buttocks of another person; Other disclosures that do not meet the same criteria for urgency or seriousness as for the urgent need for urgent medical care.	Referral and accompaniment to MOH personnel	As soon as possible (within 24 hours)
Level 3: Severe sexual violence in 8 days until the last year, but no incident within Panamanian territory	Without notification, if it occurred outside of Panamanian territory, consult with mental health.	As in level 2, but 8 days until the last year (outside of Panamanian territory).	Go to a mental health consultation, psychology and / or psychiatry staff	When detected
No reports of any specific violent act, but the participant indicates that they would like additional support.	Referral to study mental health staff, volunteer		Go to a mental health consultation, psychology and / or psychiatry staff	Within 6 hours of having been detected